Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CASP1 | P29466 | 1/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.60 |
| ▸ | ELANE | P08246 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30472945 | 1.00 | ALDH1A1 (0.72) | ALDH1A1ADORA2AKMT2AMEN1GAA | |
| SCHEMBL4649471 | 0.91 | KMT2A (0.78) | ALDH1A1KMT2AMEN1GAARAB9A | |
| SCHEMBL21107869 | 0.89 | KMT2A (0.63) | ALDH1A1ADORA2AKMT2AMEN1GAA | |
| SCHEMBL12793834 | 0.87 | CA12 (0.65) | ALDH1A1ADORA2AKMT2AMEN1GAA | |
| SCHEMBL29842449 | 0.86 | ALDH1A1 (0.64) | ALDH1A1ADORA2AKMT2AMEN1GAA | |
| SCHEMBL28812426 | 0.86 | ALDH1A1 (0.64) | ALDH1A1ADORA2AKMT2AMEN1GAA | |
| SCHEMBL29016384 | 0.86 | ALDH1A1 (0.57) | ALDH1A1ADORA2AKMT2AMEN1GAA | |
| SCHEMBL28271625 | 0.85 | ALDH1A1 (1.00) | ALDH1A1ADORA2AKMT2AMEN1GAA | |
| SCHEMBL11990862 | 0.84 | ALDH1A1 (0.70) | ALDH1A1ADORA2AKMT2AMEN1GAA | |
| SCHEMBL9277245 | 0.84 | KMT2A (0.69) | ALDH1A1KMT2AMEN1GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585069-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2013-05-01 | — | — | EP | claimed |
| EP-1973886-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | claimed |
| WO-2012006004-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | claimed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | claimed |
| EP-2385042-A1 | Prokineticin 1 receptor antagonists | Janssen Pharmaceutica N.V. (BE) | 2011-11-09 | — | — | EP | claimed |
| US-8039028-B2 | Use of an extract of the orchid Vanda coerulea as a skin hydrating agent | LVMH REACHERCHE (FR) | 2011-10-18 | — | — | US | claimed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | claimed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | claimed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | claimed |
| EP-1976528-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-08 | — | — | EP | claimed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | claimed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| US-4124375-A | Substituted phthalimides for regulating the growth of plants | MONSANTO COMPANY (US) | 1978-11-07 | — | — | US | claimed |
| CN-117466799-A | Preparation method of N-substituted phthalimide compound | 西北师范大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-115448868-B | Method for strengthening catalytic hydrogenation reaction of nitro compound | 青海黄河上游水电开发有限责任公司西宁太阳能电力分公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-116535344-A | Preparation method of phthalimide compound | 华南理工大学 | 2023-08-04 | — | — | CN | disclosed |
| EP-0526488-B1 | BENZYLPHOSPHONIC ACID TYROSINE KINASE INHIBITORS | PFIZER (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5326905-A | Benzylphosphonic acid tyrosine kinase inhibitors | PFIZER INC. (US) | 1994-07-05 | — | — | US | disclosed |
| WO-1991015495-A1 | BENZYLPHOSPHONIC ACID TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 1991-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | PROKR1, OPRL1, PROKR2 | ALDH1A1 1573/4885ADORA2A 162/4885KMT2A 4496/4885 |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | ALDH1A1 3674/4885ADORA2A 707/4885KMT2A 4664/4885 |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | ALDH1A1 4419/4885ADORA2A 510/4885KMT2A 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.